Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital

Pediatr Infect Dis J. 2010 Dec;29(12):1133-5. doi: 10.1097/INF.0b013e3181ed18ab.

Abstract

Fecal specimens from children presenting to Texas Children's Hospital with acute gastroenteritis were tested for the presence of rotavirus. Children were grouped according to vaccination status, and pentavalent rotavirus vaccine effectiveness was calculated. Pentavalent rotavirus vaccine effectiveness against severe rotavirus gastroenteritis was sustained during the first 2 years of the vaccination program. Overall 3-dose effectiveness was 83% to 86%; it was 92% to 93% among children 6 to 11 months of age and 78% to 84% among children ≥12 months of age.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age Factors
  • Feces / virology
  • Gastroenteritis / epidemiology*
  • Gastroenteritis / prevention & control*
  • Gastroenteritis / virology
  • Hospitals, Pediatric
  • Humans
  • Infant
  • Infant, Newborn
  • Rotavirus Infections / epidemiology*
  • Rotavirus Infections / immunology
  • Rotavirus Infections / prevention & control*
  • Rotavirus Vaccines / immunology*
  • Texas
  • Urban Population
  • Vaccines, Attenuated / immunology

Substances

  • RotaTeq
  • Rotavirus Vaccines
  • Vaccines, Attenuated